Nexopamil racemate

Cat. No.: HY-101727: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined Ca²⁺/5-HT₂ antagonist on thrombus formation in vivo and on platelet aggregation in vitro.

For research use only. We do not sell to patients.

Nexopamil racemate Chemical Structure

CAS No. : 116759-35-4

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Nexopamil racemate:

Nexopamil Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Calcium Channel Isoform Specific Products:

View All Isoforms

N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

View All 5-HT Receptor Isoform Specific Products:

View All Isoforms

5-HT₁ Receptor 5-HT₂ Receptor 5-HT₃ Receptor 5-HT₄ Receptor 5-HT₅ Receptor 5-HT₆ Receptor 5-HT₇ Receptor 5-HT Receptor

Biological Activity
Purity & Documentation
References
Customer Review

Description

Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined Ca²⁺/5-HT₂ antagonist on thrombus formation in vivo and on platelet aggregation in vitro.

IC₅₀ & Target

5-HT₂ Receptor

In Vitro

Serotonin-induced platelet aggregation in dog platelet-rich plasma (PRP) in vitro is most potently inhibited by Nexopamil (IC₅₀ 81 nM) ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Nexopamil (0.05 mg/kg) completely abolishes cyclic flow reductions (CFRs) during the first 30 min after application without significantly altering hemodynamics^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

404.59

Formula

C₂₄H₄₀N₂O₃

CAS No.

116759-35-4

SMILES

N#CC(C(C)C)(CCCN(CCCCCC)C)C1=CC(OC)=C(OC)C(OC)=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Kirchengast M, et al. Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94. [Content Brief]